Suna Onengut-Gumuscu

Apr 6, 2024 | nature.com | Jamie Felton |S. Alice Long |Suna Onengut-Gumuscu |Stephen S. Rich |dianna perez |Linda A. DiMeglio | +2 more

AbstractIslet autoantibodies form the foundation for type 1 diabetes (T1D) diagnosis and staging, but heterogeneity exists in T1D development and presentation. We hypothesized that autoantibodies can identify heterogeneity before, at, and after T1D diagnosis, and in response to disease-modifying therapies.

Feb 26, 2024 | ophthalmologyscience.org | Rachel Miller |Josyf C. Mychaleckyj |Suna Onengut-Gumuscu |Trevor J. Orchard

To perform a prospective epigenome-wide association study of DNA methylation (DNAm) and 28-year proliferative diabetic retinopathy (PDR) incidence in type 1 diabetes (T1D). Prospective observational cohort study. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood-onset (< 17 years) T1D. Stereoscopic fundus photographs were taken in fields 1, 2, and 4 at baseline, 2, 4, 6, 8, 16, 23, and 28 years after DNAm measurements.

Oct 4, 2023 | nature.com | S. Alice Long |Suna Onengut-Gumuscu |Stephen S. Rich |Linda A. DiMeglio |Emily Sims

AbstractType 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing beta cells. Prevention efforts have focused on immune modulation and supporting beta cell health before or around diagnosis; however, heterogeneity in disease progression and therapy response has limited translation to clinical practice, highlighting the need for precision medicine approaches to T1D disease modification.